New study from The Lundquist Institute can help stop the spread of superbugs
Investigator(s):
Kabir Yadav, MDCM, MS, MSHS, FACEP
LOS ANGELES — A new study from The Lundquist Institute shows a reliable, repeatable way to reduce the unnecessary use of antibiotics in emergency departments and urgent care centers. Overusing antibiotics does not help patients, wastes money, and more importantly is accelerating the epidemic of drug-resistant bacteria—or “superbugs.”
Study from The Lundquist Institute finds sub-dissociative doses useful for acute flare-ups
Investigator(s):
David Tanen, PhD
LOS ANGELES — A study from The Lundquist Institute shows that modest doses of ketamine can effectively treat acute exacerbations of chronic pain, providing physicians with another proven option aside from addictive opioids, which have devastated communities and resulted in thousands of early deaths in recent years.
Chlebowski presented findings at San Antonio Breast Cancer Symposium on Friday
Investigator(s):
Rowan T Chlebowski, MD, PhD
SAN ANTONIO — In a Friday morning presentation at the San Antonio Breast Cancer Symposium, one of the biggest international conferences on breast cancer,
The Lundquist Institute investigator Dr. Rowan Chlebowski shared new data that could help dramatically reduce the risk of breast cancer in postmenopausal women who are on hormone therapy.
Study from The Lundquist Institute shows viable alternative to intravenous treatment
Investigator(s):
David Tanen, PhD
LOS ANGELES — Findings from a study from The Lundquist Institute could reduce a major source of headaches for severe migraine sufferers: hospital visits.
Many people suffering from migraine headaches can control them at home through common oral medications such as sumatriptan, but there’s a substantial population that requires professional treatment to mitigate the unbearable pain. For the last four decades, that treatment has consisted of the insertion of an intravenous line to pump medicine—most commonly prochlorperazine—directly into the patient’s bloodstream.
The Lundquist Institute investigator Dr. Matthew Budoff presented results at AHA conference
Study shows The Lundquist Institute is top-tier venue for pharmaceutical research
Investigator(s):
Matthew Budoff, MD
PHILADELPHIA — Findings from a new study provide a promising pathway toward reducing the impact of heart disease, as the data shows that Vascepa, a drug derived from omega-3 oils that is commonly used to treat hypertriglyceridemia, a disease that causes elevated fat levels in blood, also reduces the progression of heart disease.
Leading Biomedical Innovators Honored at The Lundquist Institute Legends Celebration 2019
Investigator(s):
Richard Casaburi, PhD, MD
LOS ANGELES – The Lundquist Institute, one of the nation’s leading nonprofit biomedical research institutes, hosted its 16th Annual Legends celebration on November 12 honoring two highly distinguished researchers for their groundbreaking innovations and outstanding service in finding solutions to the most pressing medical problems of our day.
E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute (formerly known as LA BioMed) and the University of Rochester.
Investigator(s):
Virender Rehan, MD
LOS ANGELES — E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute (formerly known as LA BioMed) and the University of Rochester.
Dr. Sherwin Isenberg’s life-changing research could prevent thousands of babies from going blind.
Investigator(s):
Sherwin Isenberg, MD
LOS ANGELES — Neonatal intensive care units (NICUs) are medical miracles, helping babies who would likely perish without technology and medical care, thrive. Alas, they often have a tragic side effect: many premature newborns in NICU units develop blindness. This blindness results from a condition called Retinopathy of Prematurity (ROP), caused when infants are exposed to normal or excessive supplementary oxygen, a common necessity in the NICU.
Funding launches study on link between healthy lifestyles and sperm quality
Investigator(s):
Christina Chung-Lun Wang, MD, Ronald Swerdloff, MD
LOS ANGELES – A team of investigators from The Lundquist Institute (formerly known as LA BioMed), will receive $2.2 million of a total $7 million grant award from the National Institutes of Health (NIH) to research male reproductive health as part of a comprehensive study led by University of Nevada at Reno under the direction of Wei Yan, M.D., Ph.D.
About 20 percent of Americans of childbearing age face fertility problems. Of the 10 percent of infertile couples in the United States, one-third are due to the male’s infertility, according to the NIH.
24 of California’s top biotech startups shared their products at October 14 event
Investigator(s):
The Lundquist Institute
LOS ANGELES — Local startups working on everything from a device that diagnoses children’s ear infections with the push of a button, to a gene therapy for those susceptible to addiction that could replace opioids as a painkiller, to a diagnostic that can provide a highly specific analysis of cancerous lesions shared their groundbreaking innovations at the Lundquist Institute’s (formerly known as LA BioMed) sixth annual Innovation Showcase on October 14.